165 related articles for article (PubMed ID: 37276911)
21. Pan-Cancer Analysis of PDIA3: Identifying It as a Potential Biomarker for Tumor Prognosis and Immunotherapy.
Zhang J; Wang K; Hainisayimu T; Li H
Oxid Med Cell Longev; 2022; 2022():9614819. PubMed ID: 36046686
[TBL] [Abstract][Full Text] [Related]
22. IMPDH1, a prognostic biomarker and immunotherapy target that correlates with tumor immune microenvironment in pan-cancer and hepatocellular carcinoma.
Liu C; Zhang W; Zhou X; Liu L
Front Immunol; 2022; 13():983490. PubMed ID: 36618420
[TBL] [Abstract][Full Text] [Related]
23. The prognostic and immunological role of MYB: from bladder cancer validation to pan-cancer analysis.
Cui X; Zhang C; Zhang L; Yan H
Biosci Rep; 2023 Apr; 43(4):. PubMed ID: 36994664
[TBL] [Abstract][Full Text] [Related]
24. An association between ATP7B expression and human cancer prognosis and immunotherapy: a pan-cancer perspective.
Zhang Z; Zhang A; Shi Y; Zhao Z; Zhao Z
BMC Med Genomics; 2023 Nov; 16(1):307. PubMed ID: 38037104
[TBL] [Abstract][Full Text] [Related]
25. Pan-cancer analysis of N4-acetylcytidine adaptor THUMPD1 as a predictor for prognosis and immunotherapy.
Li K; Liu J; Yang X; Tu Z; Huang K; Zhu X
Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34762107
[TBL] [Abstract][Full Text] [Related]
26. Sperm Autoantigenic Protein 17 Predicts the Prognosis and the Immunotherapy Response of Cancers: A Pan-Cancer Analysis.
Tu Z; Peng J; Long X; Li J; Wu L; Huang K; Zhu X
Front Immunol; 2022; 13():844736. PubMed ID: 35592314
[TBL] [Abstract][Full Text] [Related]
27. Pan-cancer analysis and experimental validation revealed the m6A methyltransferase KIAA1429 as a potential biomarker for diagnosis, prognosis, and immunotherapy.
Ma C; Zheng Q; Wang Y; Li G; Zhao M; Sun Z
Aging (Albany NY); 2023 Aug; 15(17):8664-8691. PubMed ID: 37606975
[TBL] [Abstract][Full Text] [Related]
28. Mining TCGA database for tumor mutation burden and their clinical significance in bladder cancer.
Lv J; Zhu Y; Ji A; Zhang Q; Liao G
Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32239176
[TBL] [Abstract][Full Text] [Related]
29. LncRNA WAC-AS1 expression in human tumors correlates with immune infiltration and affects prognosis.
Wang Y; Gong H; Cao Y
Hereditas; 2023 May; 160(1):26. PubMed ID: 37248547
[TBL] [Abstract][Full Text] [Related]
30. FKBP12 is a predictive biomarker for efficacy of anthracycline-based chemotherapy in breast cancer.
Xing M; Wang J; Yang Q; Wang Y; Li J; Xiong J; Zhou S
Cancer Chemother Pharmacol; 2019 Oct; 84(4):861-872. PubMed ID: 31428819
[TBL] [Abstract][Full Text] [Related]
31. Transcriptome sequencing and single-cell sequencing analysis identify GARS1 as a potential prognostic and immunotherapeutic biomarker for multiple cancers, including bladder cancer.
Nie J; Liu T; Mao T; Yang H; Deng W; Liu X; Fu B
Front Immunol; 2023; 14():1169588. PubMed ID: 37404826
[TBL] [Abstract][Full Text] [Related]
32. Immunotherapeutic Significance of a Prognostic Alternative Splicing Signature in Bladder Cancer.
Chen J; Liao Y; Li R; Luo M; Wu G; Tan R; Xiao Z
Technol Cancer Res Treat; 2022; 21():15330338221090093. PubMed ID: 35509211
[No Abstract] [Full Text] [Related]
33. IGF2BP3 overexpression predicts poor prognosis and correlates with immune infiltration in bladder cancer.
Huang W; Zhu L; Huang H; Li Y; Wang G; Zhang C
BMC Cancer; 2023 Feb; 23(1):116. PubMed ID: 36732736
[TBL] [Abstract][Full Text] [Related]
34. ANXA2 is a potential biomarker for cancer prognosis and immune infiltration: A systematic pan-cancer analysis.
Ning Y; Li Y; Wang H
Front Genet; 2023; 14():1108167. PubMed ID: 36713082
[No Abstract] [Full Text] [Related]
35. Association of TP53 and MDM2 polymorphisms with survival in bladder cancer patients treated with chemoradiotherapy.
Shinohara A; Sakano S; Hinoda Y; Nishijima J; Kawai Y; Misumi T; Nagao K; Hara T; Matsuyama H
Cancer Sci; 2009 Dec; 100(12):2376-82. PubMed ID: 19764997
[TBL] [Abstract][Full Text] [Related]
36. Pan-cancer analysis and experimental validation of DTL as a potential diagnosis, prognosis and immunotherapy biomarker.
Tang Y; Lei Y; Gao P; Jia J; Du H; Wang Q; Yan Z; Zhang C; Liang G; Wang Y; Ma W; Xing N; Cheng L; Ren L
BMC Cancer; 2023 Apr; 23(1):328. PubMed ID: 37038185
[TBL] [Abstract][Full Text] [Related]
37. KIF2C is a prognostic biomarker associated with immune cell infiltration in breast cancer.
Liu S; Ye Z; Xue VW; Sun Q; Li H; Lu D
BMC Cancer; 2023 Apr; 23(1):307. PubMed ID: 37016301
[TBL] [Abstract][Full Text] [Related]
38. MDM2 SNP309 promoter polymorphism and p53 mutations in urinary bladder carcinoma stage T1.
Olsson H; Hultman P; Rosell J; Söderkvist P; Jahnson S
BMC Urol; 2013 Jan; 13():5. PubMed ID: 23356517
[TBL] [Abstract][Full Text] [Related]
39. A Pan-Cancer Analysis Reveals the Prognostic and Immunotherapeutic Value of Stanniocalcin-2 (STC2).
Jiang ZH; Shen X; Wei Y; Chen Y; Chai H; Xia L; Leng W
Front Genet; 2022; 13():927046. PubMed ID: 35937984
[No Abstract] [Full Text] [Related]
40. MDM2 SNP309 modifies the prognostic significance of the p53 mutational status in patients with ovarian cancer.
Hofstetter G; Berger A; Bauer EM; Schuster E; Wolf A; Chamson M; Müller-Holzner E; Reimer D; Braicu EI; Sehouli J; Ulmer H; Cacsire Castillo-Tong D; Zeillinger R; Concin N
Oncol Rep; 2012 Mar; 27(3):673-7. PubMed ID: 22134502
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
